RAPT Historical Income Statement

RAPT Stock

USD 1.08 0.03 2.86%

Historical analysis of RAPT Therapeutics income statement accounts such as Other Operating Expenses of 71.6 M, Research Development of 57 M, Total Operating Expenses of 71.6 M or Reconciled Depreciation of 944.2 K can show how well RAPT Therapeutics performed in making a profits. Evaluating RAPT Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of RAPT Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining RAPT Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether RAPT Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

About RAPT Income Statement Analysis

RAPT Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to RAPT Therapeutics shareholders. The income statement also shows RAPT investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

RAPT Therapeutics Income Statement Chart

At this time, RAPT Therapeutics' Interest Expense is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 10.8 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 952.3 K in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Net Income Applicable To Common Shares

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of RAPT Therapeutics. It is also known as RAPT Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from RAPT Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into RAPT Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.At this time, RAPT Therapeutics' Interest Expense is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 10.8 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 952.3 K in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	996K	1.0M	1.1M	944.2K
Total Operating Expenses	73.0M	87.3M	127.1M	71.6M

Reconciled Depreciation Total Operating Expenses

RAPT Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Tax Provision	Gross Profit	Cost Of Revenue	Non Operating Income Net Other	Selling And Marketing Expenses
Depreciation And Amortization		-0.76	-0.7	0.77	0.82	0.77	-0.67	0.78	-0.7	0.99	0.79	-0.53	0.79	0.78	0.64	-0.41	-0.38	0.19	0.54
Selling General Administrative	-0.76		0.99	-0.91	-0.94	-0.91	0.98	-0.91	0.99	-0.81	-0.93	0.69	-0.92	-0.89	-0.73	0.18	0.77	0.28	-0.5
Other Operating Expenses	-0.7	0.99		-0.93	-0.94	-0.93	1.0	-0.93	1.0	-0.77	-0.93	0.75	-0.93	-0.88	-0.74	0.08	0.82	0.34	-0.54
Operating Income	0.77	-0.91	-0.93		1.0	1.0	-0.93	1.0	-0.93	0.83	1.0	-0.91	1.0	0.92	0.8	0.1	-0.83	-0.28	0.8
Net Income From Continuing Ops	0.82	-0.94	-0.94	1.0		1.0	-0.94	1.0	-0.94	0.87	1.0	-0.86	1.0	0.94	0.81	0.01	-0.81	-0.25	0.75
Ebit	0.77	-0.91	-0.93	1.0	1.0		-0.93	1.0	-0.93	0.83	1.0	-0.91	1.0	0.92	0.8	0.1	-0.83	-0.28	0.8
Research Development	-0.67	0.98	1.0	-0.93	-0.94	-0.93		-0.93	1.0	-0.75	-0.93	0.76	-0.93	-0.88	-0.74	0.04	0.83	0.35	-0.55
Ebitda	0.78	-0.91	-0.93	1.0	1.0	1.0	-0.93		-0.93	0.83	1.0	-0.9	1.0	0.92	0.8	0.09	-0.83	-0.28	0.8
Total Operating Expenses	-0.7	0.99	1.0	-0.93	-0.94	-0.93	1.0	-0.93		-0.77	-0.93	0.75	-0.93	-0.88	-0.74	0.08	0.82	0.34	-0.54
Reconciled Depreciation	0.99	-0.81	-0.77	0.83	0.87	0.83	-0.75	0.83	-0.77		0.85	-0.6	0.85	0.82	0.68	-0.36	-0.46	0.13	0.58
Income Before Tax	0.79	-0.93	-0.93	1.0	1.0	1.0	-0.93	1.0	-0.93	0.85		-0.89	1.0	0.93	0.81	0.06	-0.82	-0.26	0.78
Total Other Income Expense Net	-0.53	0.69	0.75	-0.91	-0.86	-0.91	0.76	-0.9	0.75	-0.6	-0.89		-0.89	-0.73	-0.64	-0.43	0.8	0.41	-0.94
Net Income	0.79	-0.92	-0.93	1.0	1.0	1.0	-0.93	1.0	-0.93	0.85	1.0	-0.89		0.92	0.8	0.06	-0.82	-0.26	0.79
Income Tax Expense	0.78	-0.89	-0.88	0.92	0.94	0.92	-0.88	0.92	-0.88	0.82	0.93	-0.73	0.92		0.94	0.03	-0.82	-0.2	0.64
Tax Provision	0.64	-0.73	-0.74	0.8	0.81	0.8	-0.74	0.8	-0.74	0.68	0.81	-0.64	0.8	0.94		0.19	-0.72	-0.05	0.6
Gross Profit	-0.41	0.18	0.08	0.1	0.01	0.1	0.04	0.09	0.08	-0.36	0.06	-0.43	0.06	0.03	0.19		-0.4	-0.45	0.45
Cost Of Revenue	-0.38	0.77	0.82	-0.83	-0.81	-0.83	0.83	-0.83	0.82	-0.46	-0.82	0.8	-0.82	-0.82	-0.72	-0.4		0.7	-0.62
Non Operating Income Net Other	0.19	0.28	0.34	-0.28	-0.25	-0.28	0.35	-0.28	0.34	0.13	-0.26	0.41	-0.26	-0.2	-0.05	-0.45	0.7		-0.19
Selling And Marketing Expenses	0.54	-0.5	-0.54	0.8	0.75	0.8	-0.55	0.8	-0.54	0.58	0.78	-0.94	0.79	0.64	0.6	0.45	-0.62	-0.19

Click cells to compare fundamentals

RAPT Therapeutics Account Relationship Matchups

RAPT Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.3M	1.1M	996K	1.0M	1.2M	952.3K
Interest Expense	2.6M	2.4M	996K	1.0M	1.2M	1.3M
Selling General Administrative	8.7M	12.8M	16.0M	20.2M	26.1M	14.6M
Other Operating Expenses	43.6M	58.3M	73.0M	87.3M	127.1M	71.6M
Operating Income	(43.6M)	(53.2M)	(69.2M)	(85.8M)	(127.1M)	(120.7M)
Net Income From Continuing Ops	(43.0M)	(52.9M)	(69.2M)	(83.8M)	(108.9M)	(103.4M)
Ebit	(43.6M)	(53.2M)	(69.2M)	(85.8M)	(127.1M)	(120.7M)
Research Development	34.9M	45.5M	57.0M	67.1M	101.0M	57.0M
Ebitda	(42.3M)	(52.1M)	(68.2M)	(84.7M)	(125.8M)	(119.6M)
Total Operating Expenses	43.6M	58.3M	73.0M	87.3M	127.1M	71.6M
Reconciled Depreciation	1.3M	1.1M	996K	1.0M	1.1M	944.2K
Income Before Tax	(42.3M)	(51.9M)	(69.2M)	(83.8M)	(116.8M)	(111.0M)
Total Other Income Expense Net	1.3M	1.3M	5K	2.0M	10.3M	10.8M
Net Income Applicable To Common Shares	(43.0M)	(52.9M)	(69.2M)	(83.8M)	(75.5M)	(79.2M)
Net Income	(43.0M)	(52.9M)	(68.2M)	(81.9M)	(116.8M)	(111.0M)
Income Tax Expense	660K	990K	(996K)	(2.0M)	(1.8M)	(1.7M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

RAPT Historical Income Statement

About RAPT Income Statement Analysis

RAPT Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Net Income Applicable To Common Shares

RAPT Therapeutics income statement Correlations

RAPT Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

RAPT Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for RAPT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Selling And Marketing Expenses	- 0.94	Total Other Income Expense Net
Total Operating Expenses	- 0.94	Net Income From Continuing Ops
Research Development	- 0.94	Net Income From Continuing Ops
Net Income From Continuing Ops	- 0.94	Other Operating Expenses
Net Income From Continuing Ops	- 0.94	Selling General Administrative
Net Income	- 0.93	Total Operating Expenses